BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36788061)

  • 1. Hepatic Sarcomatoid Carcinoma Is an Aggressive Hepatic Neoplasm Sharing Common Molecular Features With Its Conventional Carcinomatous Counterparts.
    Yoshuantari N; Jeng YM; Liau JY; Lee CH; Tsai JH
    Mod Pathol; 2023 Jan; 36(1):100042. PubMed ID: 36788061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular features of primary hepatic undifferentiated carcinoma.
    Tsai JH; Jeng YM; Lee CH; Liau JY
    Mod Pathol; 2022 May; 35(5):680-687. PubMed ID: 34949765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment and prognostic implications of strong PD-L1 expression in primary hepatic sarcomatoid carcinoma.
    Radhakrishnan S; Martin CA; Vij M; Subbiah K; Raju LP; Gowrishankar G; Veldore VH; Kaliamoorthy I; Rammohan A; Rela M
    Immunotherapy; 2024 Apr; 16(6):371-379. PubMed ID: 38362631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-small cell lung carcinomas with a minor sarcomatoid component and pleomorphic carcinomas are associated with high expression of programmed death ligand 1.
    Tancoš V; Farkašová A; Kviatkovská Z; Grendár M; Líšková A; Huťka Z; Plank L
    Pathol Res Pract; 2020 Dec; 216(12):153238. PubMed ID: 33059241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.
    Joseph NM; Tsokos CG; Umetsu SE; Shain AH; Kelley RK; Onodera C; Bowman S; Talevich E; Ferrell LD; Kakar S; Krings G
    J Pathol; 2019 Jun; 248(2):164-178. PubMed ID: 30690729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inter-relationship between PD-L1 expression and clinic-pathological features and driver gene mutations in pulmonary sarcomatoid carcinomas.
    Lococo F; Torricelli F; Rossi G; Alifano M; Damotte D; Rapicetta C; Tamagnini I; Cavazza A; Piana S; Galeone C; Paci M; Ciarrocchi A
    Lung Cancer; 2017 Nov; 113():93-101. PubMed ID: 29110857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sarcomatoid hepatocellular carcinoma is distinct from ordinary hepatocellular carcinoma: Clinicopathologic, transcriptomic and immunologic analyses.
    Morisue R; Kojima M; Suzuki T; Nakatsura T; Ojima H; Watanabe R; Sugimoto M; Kobayashi S; Takahashi S; Konishi M; Ishii G; Gotohda N; Fujiwara T; Ochiai A
    Int J Cancer; 2021 Aug; 149(3):546-560. PubMed ID: 33662146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management.
    Gupta S; Cheville JC; Jungbluth AA; Zhang Y; Zhang L; Chen YB; Tickoo SK; Fine SW; Gopalan A; Al-Ahmadie HA; Sirintrapun SJ; Blum KA; Lohse CM; Hakimi AA; Thompson RH; Leibovich BC; Berger MF; Arcila ME; Ross DS; Ladanyi M; Antonescu CR; Reuter VE
    Mod Pathol; 2019 Sep; 32(9):1344-1358. PubMed ID: 30996253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic heterogeneity and predictive biomarker for pulmonary sarcomatoid carcinomas.
    Qin J; Chen B; Li C; Yan J; Lu H
    Cancer Genet; 2021 Jan; 250-251():12-19. PubMed ID: 33217678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New therapeutic targets for pulmonary sarcomatoid carcinomas based on their genomic and phylogenetic profiles.
    Nakagomi T; Goto T; Hirotsu Y; Shikata D; Yokoyama Y; Higuchi R; Amemiya K; Okimoto K; Oyama T; Mochizuki H; Omata M
    Oncotarget; 2018 Feb; 9(12):10635-10649. PubMed ID: 29535832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphoepithelioma-like Intrahepatic Cholangiocarcinoma Is a Distinct Entity With Frequent pTERT/TP53 Mutations and Comprises 2 Subgroups Based on Epstein-Barr Virus Infection.
    Tsai JH; Liau JY; Lee CH; Jeng YM
    Am J Surg Pathol; 2021 Oct; 45(10):1409-1418. PubMed ID: 33859071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic and Immunohistochemical Characterization of Sarcomatoid Chromophobe Renal Cell Carcinoma: An Analysis of 22 Cases.
    Whaley RD; Cheng L
    Am J Surg Pathol; 2022 Sep; 46(9):1171-1179. PubMed ID: 35687360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed death ligand-1 expression levels, clinicopathologic features, and survival in surgically resected sarcomatoid lung carcinoma.
    Ağaçkıran Y; Aksu F; Akyürek N; Ercan C; Demiröz M; Aksu K
    Asia Pac J Clin Oncol; 2021 Jun; 17(3):280-288. PubMed ID: 32929886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of immune infiltration in sarcomatoid hepatocellular carcinoma.
    Luo C; Xin H; Yin D; Zhao T; Hu Z; Zhou Z; Sun R; Yao N; Sun Q; Fan J; Huang X; Zhou J; Zhou S
    Aging (Albany NY); 2021 Jun; 13(11):15126-15138. PubMed ID: 34081621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
    Kim S; Kim MY; Koh J; Go H; Lee DS; Jeon YK; Chung DH
    Eur J Cancer; 2015 Nov; 51(17):2698-707. PubMed ID: 26329973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sarcomatoid carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical analysis of 14 patients.
    Ikegami H; Iwasaki H; Ohjimi Y; Takeuchi T; Ariyoshi A; Kikuchi M
    Hum Pathol; 2000 Mar; 31(3):332-40. PubMed ID: 10746676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian squamous cell carcinoma associated with teratoma: a report of six cases with genomic analysis.
    Liang Y; Ruan H; Yu M; Lü B
    Pathology; 2023 Dec; 55(7):966-973. PubMed ID: 37739924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational landscape of combined hepatocellular carcinoma and cholangiocarcinoma, and its clinicopathological significance.
    Sasaki M; Sato Y; Nakanuma Y
    Histopathology; 2017 Feb; 70(3):423-434. PubMed ID: 27634656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1).
    Velcheti V; Rimm DL; Schalper KA
    J Thorac Oncol; 2013 Jun; 8(6):803-5. PubMed ID: 23676558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.